TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36227234
Drug: Rest Redistribution
Normalized name: Rest Simply
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rest Redistribution with Heavier Loads (RR + L): 4 sets of (2 × 5) repetitions with 90-second interset rest and 30-second intraset rest using 75% BS 1RM
Study: 33785496
Drug: Physiotherapist-led exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiotherapist-led exercise therapy
Study: 32065775
Drug: Blood pressure-lowering
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood pressure-lowering medication
Study: 32065775
Drug: Lipid-lowering medications
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-lowering medications
Study: 32065775
Drug: Any CVD
Normalized name: Vibrio cholerae CVD 103-HGR strain live antigen Oral Suspension [Vaxchora]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any CVD prevention medication
Study: 32065775
Drug: Blood pressure-lowering
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood pressure-lowering medication use in high CVD risk
Study: 32350058
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy alone (antiplatelet medication such as aspirin or anticoagulation)
Study: 32042286
Drug: Fluticasone furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone furoate 50 µg once daily
Study: 34763937
Drug: Enzalutamide 160
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Enzalutamide 160 mg daily until progression or treatment discontinuation
Study: 34494113
Drug: BEP supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: BEP supplement
Study: 34494113
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (daily iron‐folic acid tablet)
Study: 33955348
Drug: Almond consumption
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almond consumption (1.5 oz daily with breakfast and as an afternoon snack)
Study: 32975829
Drug: Portable gluten
Approvals — FDA: no, EMA: no, PMDA: no
Description: Portable gluten sensor (low, medium, and high numbers of single-use capsules)
Study: 36203046
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily (b.i.d.) dexamethasone 0.1%/netilmicin 0.3% (Netildex) ophthalmic gel
Study: 36203046
Drug: Four times
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four times daily (q.i.d.) dexamethasone 0.1%/netilmicin 0.3% (Netildex) eye drops
Study: 34278611
Drug: ZOL 5-mg
Normalized name: Zol
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: ZOL 5-mg infusion
Study: 35799973
Drug: Internet-delivered cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-delivered cognitive-behavioral therapy
Study: 33704353
Drug: Ablative radiation
Normalized name: ABL
DrugBank: Lauric acid (DB03017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ablative radiation therapy (A‐RT) at 98 Gy biologically effective dose
Study: 33704353
Drug: Ablative radiation
Normalized name: ABL
DrugBank: Lauric acid (DB03017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ablative radiation therapy (A‐RT)
Study: 36862472
Drug: Cognitive-behavioral couple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral couple therapy (CBCT)
Study: 36451139
Drug: EMDR (Eye
Approvals — FDA: no, EMA: no, PMDA: no
Description: EMDR (Eye Movement Desensitization and Reprocessing) therapy, 3 to 5 sessions
Study: 35694079
Drug: Inhalation groups
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation groups (Desflurane, Propofol, Sevoflurane)
Study: 32585039
Drug: Oral ibuprofen
Normalized name: ibuprofen Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ibuprofen (7.5 mg/kg body weight)
Study: 32250530
Drug: Lyo avexitide
Normalized name: Avexitide
DrugBank: Avexitide (DB14806)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lyo avexitide (exendin 9-39) at ascending doses, administered SC twice daily for 3 days
Study: 32250530
Drug: Liq avexitide
Normalized name: Avexitide
DrugBank: Avexitide (DB14806)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liq avexitide (exendin 9-39) at a fixed dose of 30 mg, administered SC twice daily for 3 days
Study: 35039301
Drug: Betamethasone valerate
Normalized name: Betamethasone Valerate
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betamethasone valerate ointment (5 times a day)
Study: 35039301
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (usual oral hygiene guidance only)
Study: 35765222
Drug: RT001 (2.88
Approvals — FDA: no, EMA: no, PMDA: no
Description: RT001 (2.88 g/day, increased to 8.64 g/day as tolerated)
Study: 35765222
Drug: RT001 (5.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: RT001 (5.6 ± 1.6 g/day; dose range, 1.92 to 8.64 g/day)
Study: 34389633
Drug: GSK2982772 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2982772 60 mg three times daily for 42 days
Study: 33357510
Drug: Intravenous carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous carboplatin (AUC5 or AUC6) and intravenous paclitaxel (175 mg/m2) on day 1 of every 21‐day cycle (control group)
Study: 33357510
Drug: Intravenous carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous carboplatin (AUC5 or AUC6) on day 1 and intravenous dose‐fractionated paclitaxel (80 mg/m2) on days 1, 8, and 15 of every 21‐day cycle (group 2)
Study: 33357510
Drug: Intravenous dose‐fractionated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dose‐fractionated carboplatin (AUC2) and intravenous dose‐fractionated paclitaxel (80 mg/m2) on days 1, 8, and 15 of every 21‐day cycle (group 3)
Study: 32474130
Drug: 5-session telephone-administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-session telephone-administered motivational interviewing plus behavioral skills training (teleMI+BST)
Study: 32474130
Drug: 5-session telephone-administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-session telephone-administered coping effectiveness training (teleCET)
Study: 32186013
Drug: Jiawei Xiaoyao
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jiawei Xiaoyao (JWXY) capsules
Study: 35129242
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (TAU; n = 59)
Study: 35129242
Drug: HIV clinic‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV clinic‐based extended‐release naltrexone (XR‐NTX) among those initiating medication
Study: 35129242
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (TAU) among those initiating medication
Study: 34486272
Drug: Lactoginal vaginal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactoginal vaginal probiotic after standard antibacterial therapy
Study: 32273244
Drug: Sleep improvement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sleep improvement intervention (3 weekly sessions lasting 90 to 120 minutes)
Study: 32847917
Drug: Xueshuantong injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xueshuantong injection (lyophilised) (XST)
Study: 32847917
Drug: 1/20th dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1/20th dose of Xueshuantong injection (lyophilised) (Control)
Study: 39755573
Drug: Standard oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard oxygen therapy (control group)
Study: 32444250
Drug: Azathioprine 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azathioprine 2.5 mg/kg/day with oral curcumin 3 g/day
Study: 34432204
Drug: Kangfuyan Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kangfuyan Capsules (4 capsules, 3 times daily for 12 weeks)
Study: 34432204
Drug: Gongyanping Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gongyanping Capsules (control group, 4 capsules, 3 times daily for 12 weeks)
Study: 33966118
Drug: metreleptin treatment
Normalized name: Metreleptin
DrugBank: Metreleptin (DB09046)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: metreleptin treatment
Study: 32581041
Drug: Cisplatin and
Normalized name: A micelle drug formulation composed of cisplatin and mPEG-poly(l-Glu) diblock copolymer with 1,3-propanediyl linkagecisplatin is incorporated in polymeric micelles via polymer-metal complex formation with cis-geometry of PT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin and docetaxel (first-line treatment)
Study: 36154603
Drug: Pregabalin 300
Normalized name: pregabalin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin 300 mg tablet 90 minutes before surgery
Study: 36154603
Drug: Clonidine 150
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine 150 µg tablet 90 minutes before surgery
Study: 32982212
Drug: Ensifentrine 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ensifentrine 0.75 to 6mg twice daily
Study: 33120137
Drug: Cognitive-behavioural group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioural group therapy (N = 67)
Study: 33120137
Drug: Mindfulness-based stress
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-based stress reduction group therapy (N = 58)
Study: 36327169
Drug: Low-dose alfaxalone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose alfaxalone (LDA) 2 mg/kg
Study: 36327169
Drug: High-dose alfaxalone
Normalized name: alfaxalone
DrugBank: Alfaxalone (DB11371)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose alfaxalone (HDA) 5 mg/kg
Study: 35621299
Drug: Medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medroxyprogesterone acetate (20 mg from day 1 of the menstrual cycle till trigger day)
Study: 35621299
Drug: Gonadotropin-releasing hormone
Normalized name: Gonadotropin-releasing hormone
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gonadotropin-releasing hormone antagonist (Cetrorelix 0.25 mg s/c from the day leading follicle reached 14 mm until trigger day)
Study: 35621299
Drug: Gonadotropin-releasing hormone
Normalized name: Gonadotropin-releasing hormone
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gonadotropin-releasing hormone antagonist
Study: 35222900
Drug: Conventional stroke
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional stroke treatment and nursing
Study: 34154628
Drug: Drug-coated balloon
Normalized name: CATHETER,BALLOON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-coated balloon (DCB) treatment group (balloon group, n = 38)
Study: 34154628
Drug: Drug-eluting stent
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-eluting stent (DES) treatment group (stent group, n = 42)
Study: 34154628
Drug: Drug-coated balloon
Normalized name: CATHETER,BALLOON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-coated balloon (DCB) treatment group (balloon group)
Study: 34154628
Drug: Drug-eluting stent
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-eluting stent (DES) treatment group (stent group)
Study: 35069956
Drug: Hyperbaric ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric ropivacaine 15 mg (Group R)
Study: 35069956
Drug: Hyperbaric ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric ropivacaine 15 mg with intrathecal fentanyl 20 μg (Group RF)
Study: 34865095
Drug: Local oxygen-ozone
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local oxygen-ozone therapy plus medical treatment (n=13)
Study: 34865095
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment only (Control group, n=12)
Study: 32705692
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose oral rifampin (RIF)
Study: 33121523
Drug: Innovative treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Innovative treatments
Study: 33940662
Drug: Oxa-Gel with
Normalized name: Q-Gel with Lipoic Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxa-Gel with potassium oxalate (PO)
Study: 33778994
Drug: Peer support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peer support groups (monthly for the first two months, then every three months for the remainder of the year)
Study: 36269852
Drug: Ivermectin, 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivermectin, 400 μg/kg, daily for 3 days (n=817)
Study: 32628676
Drug: Causal role
Normalized name: Roledumab
DrugBank: Roledumab (DB16317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Causal role of tyrosine‐protein phosphatase non‐receptor type substrate 1 (SHPS1; SIRPA)
Study: 35157370
Drug: GDC-0214 (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: GDC-0214 (15 mg twice daily for 14 days)
Study: 35157370
Drug: 99mTc-radiolabeled GDC-0214
Normalized name: Radiolabelled DUNP19
DrugBank: RAD 502 (DB17328)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 99mTc-radiolabeled GDC-0214 (1 mg)
Study: 37797293
Drug: Subcutaneous risankizumab
Normalized name: risankizumab
DrugBank: Risankizumab (DB14762)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous risankizumab 360 mg
Study: 37797293
Drug: Subcutaneous risankizumab
Normalized name: risankizumab
DrugBank: Risankizumab (DB14762)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous risankizumab 180 mg
Study: 35644155
Drug: Withdrawal (subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawal (subcutaneous placebo)
Study: 32420624
Drug: Initial experimental
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial experimental treatment
Study: 32420624
Drug: Initial control
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial control treatment
Study: 34384459
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy for Insomnia (CBT-I), delivered in-person or via telehealth, five weekly sessions.
Study: 35656654
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of wavelengths 660 and 810 nm
Study: 34979252
Drug: 1.5 g
Normalized name: Vaporizer Vicks 1.5 gal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g of TXA intravenously q12 hours from postadmission day 1 to the day before surgery and 1.5 g of TXA q12 hours from postoperative day 1 to postoperative day 3
Study: 34979252
Drug: 100 mL
Normalized name: PVC IV Bag 100 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mL of normal saline intravenously q12 hours from postadmission day 1 to the day before surgery and 1.5 g of TXA q12 hours from postoperative day 1 to postoperative day 3
Study: 32947619
Drug: Various therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various therapies for multiple sclerosis (10 therapies analyzed for relapses)
Study: 32947619
Drug: Various therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various therapies for multiple sclerosis (7 therapies analyzed for disability progression)
Study: 32947619
Drug: All therapies
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All therapies except intramuscular interferon beta-1a
Study: 35975762
Drug: Costoclavicular block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Costoclavicular block (CCB) with 20 ml 0.5% ropivacaine
Study: 35975762
Drug: Superior trunk
Normalized name: Sus scrofa superior gastric plexus preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Superior trunk block (STB) with 20 ml 0.5% ropivacaine
Study: 34965006
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea extract encapsulated chitosan microparticles (GTP) cream
Study: 35680173
Drug: Combined metabolic
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined metabolic medication (SINR) containing succinic acid, inosine, nicotinamide, and riboflavin, administered intravenously for 10 days followed by oral administration for 75 days
Study: 35680173
Drug: Placebo, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, administered intravenously for 10 days followed by oral administration for 75 days
Study: 35680173
Drug: Combined metabolic
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined metabolic medication (SINR)
Study: 34060685
Drug: Cervical manual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cervical manual therapy plus conventional physiotherapy
Study: 36122966
Drug: Self‐administered condition‐tailored
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self‐administered condition‐tailored psychoeducational intervention
Study: 36115616
Drug: Single-injection liposomal
Normalized name: daunorubicin liposomal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-injection liposomal bupivacaine brachial plexus nerve block (LB)
Study: 35745210
Drug: Active beetroot
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active beetroot juice (BJ) - 70 mL, 400 mg nitrate
Study: 35745210
Drug: Placebo beetroot
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo beetroot juice (BJ) - 70 mL, 0 mg nitrate
Study: 36454571
Drug: Wearing glasses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wearing glasses (e.g., sunglasses) in public spaces for 2 weeks
Study: 34551181
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) treatment
Study: 34244212
Drug: Inhibition of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhibition of Scavenger Receptor B1 (SCARB1)
Study: 32012255
Drug: Resection of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resection of the end-of-therapy mass
Study: 33896812
Drug: Hyaluronic acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic acid injection (HAI) with APM
Study: 33896812
Drug: Hyaluronic acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic acid injection (HAI) with PT
Study: 32075993
Drug: Pulsed electromagnetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed electromagnetic fields (PEMFs); specific details on dosage and duration are not available.
Study: 32075993
Drug: Placebo; specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo; specific details on dosage and duration are not available.
Study: 36705750
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate (SB) supplementation (0.3 g·kg‐1 BM)
Study: 32167433
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg polyphenols extracted from seeds of red grape (Nero di Troia cultivar) (NATUR‐OX®) for 3 months (T1)
Study: 33764636
Drug: Sildenafil 25
Normalized name: sildenafil 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil 25 mg three times per day plus guideline-recommended treatment for heart failure
Study: 33764636
Drug: Guideline-recommended treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline-recommended treatment for heart failure (ACEIs or ARBs, beta-blockers, aldosterone receptor antagonist, digoxin)
Study: 32618780
Drug: Ozone bagging
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozone bagging therapy at 70 μg/mL for 10 minutes every 3 days for 21 days
Study: 36039391
Drug: 5% topical
Normalized name: BP 5% Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% topical minoxidil solution
Study: 36039391
Drug: 5% topical
Normalized name: BP 5% Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% topical spironolactone solution
Study: 36039391
Drug: 5% topical
Normalized name: BP 5% Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% topical minoxidil and spironolactone combination
Study: 32524862
Drug: Clarithromycin 500
Normalized name: clarithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 500 mg two times per day for 5 days
Study: 34472896
Drug: Group cognitive
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group cognitive remediation therapy (CRT) with 8 group sessions over 2 months
Study: 35017617
Drug: linagliptin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: linagliptin (5 mg) + insulin
Study: 35017617
Drug: insulin alone
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: insulin alone
Study: 32889844
Drug: Buccal DEX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buccal DEX gel 0.5 µg/kg
Study: 32889844
Drug: Buccal DEX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buccal DEX gel 0.75 µg/kg
Study: 32889844
Drug: Buccal DEX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buccal DEX gel 1 µg/kg
Study: 34569457
Drug: Tummy time
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tummy time >15 minutes daily
Study: 34569457
Drug: Tummy time
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tummy time <15 minutes daily
Study: 36430138
Drug: Placebo (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1 mL of 1% lidocaine), n = 16
Study: 32397852
Drug: Topical phenylephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical phenylephrine hydrochloride
Study: 32397852
Drug: RJ101 (norepinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: RJ101 (norepinephrine releasing agent)
Study: 33782383
Drug: Open-label stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label stimulation with cognitive behavioural therapy (CBT)
Study: 32669717
Drug: AAV1/SERCA2a gene
Approvals — FDA: no, EMA: no, PMDA: no
Description: AAV1/SERCA2a gene therapy (1 × 10^13 DNase-resistant particles)